Dxcover Announces Updates to Executive Leadership Team
Retrieved on:
Tuesday, December 12, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Clinical Trials, Lung, University of Central Lancashire, School, Breast, IP, Colorectal cancer, ESMO, Patient, British Journal of Cancer, Data analysis, Algorithm, University of Strathclyde, Kidney, Prostate cancer, Machine learning, Business, Medical school, University, Central Lancashire, Cancer, Survival, Growth, Congress, Quality of life, Poster, IVDR, Innovation system, Brain, Management, Chemistry
Dxcover Limited , a clinical-stage diagnostics company pioneering Multi-Omic Spectral Analysis for early detection of multiple cancers, today announced updates to its executive management team.
Key Points:
- Dxcover Limited , a clinical-stage diagnostics company pioneering Multi-Omic Spectral Analysis for early detection of multiple cancers, today announced updates to its executive management team.
- Dxcover’s Co-Founder Prof. Matthew Baker will transition from his role as Chief Technical Officer to Chief Executive Officer.
- Another Co-Founder Dr David Palmer, who has been Chief Data Scientist since spin-out, has been named Chief Technical Officer.
- “I want to express my deepest gratitude to Mark for his dedicated and unwavering leadership in the first phase of Dxcover’s story.